Novotech, a globally recognized full-service biotech specialist clinical research organization (CRO), announces that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in the company, with the additional capital earmarked to accelerate its global growth. Existing investor TPG will also reinvest through its TPG Asia fund. Novotech, headquartered in Singapore with a global presence across more than 30 offices, is one of the world’s leading full-service clinical CROs, providing biotech and small- to mid-sized pharmaceutical companies with an accelerated path to market.
Read the full article: Novotech Welcomes New Investment from GIC, Temasek, and Existing Investor TPG to Accelerate Global Growth //
Source: https://www.businesswire.com/news/home/20250330371581/en/Novotech-Welcomes-New-Investment-From-GIC-Temasek-and-Existing-Investor-TPG-to-Accelerate-Global-Growth